Novartis Aims Double Edged Attack With Galvus And Jalra To Take On Merck's Januvia In India
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The fight for a share of India's growing diabetes drugs market is set to become more fierce as Novartis is exploring an alliance with USV for promoting its type 2 anti-diabetes drug brand Jalra (vildagliptin)
You may also be interested in...
Asia Spotlight: India Case Study – Novartis’ Galvus Inches Closer To Merck’s Januvia As Battle For Brand Supremacy Rages On
Three years after Novartis and MSD launched their DPP-4 inhibitors in India, PharmAsia News takes a closer look at who will come out on top.
India Case Study: Novartis’ Galvus Inches Closer To Merck’s Januvia As Battle For Brand Supremacy Rages On
Three years after Novartis and MSD launched their DPP-4 inhibitors in India, PharmAsia News takes a closer look at who will come out on top.
On Heels Of Emerging Markets Deal, Merck Ropes In India's Sun Pharma To Boost Januvia Sales
MUMBAI - In an attempt to add more teeth to its rapidly growing anti-diabetes franchise in India, Merck & Co.'s affiliate MSD India and Sun Pharmaceutical Industries Ltd. jointly announced the formation of an "India-specific strategic partnership" under which Sun will have the right to market, promote and distribute MSD's star products Januvia (sitagliptin) and Janumet (sitagliptlin/metformin) under different brand names